Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.

Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.

J Med Econ. 2018 Nov 27;:1-13

Authors: Hamdy Elsisi G, Nada Y, Rashad N, Carapinha J

Abstract
Background In light of constrained budgets and the need to fund efficient treatment options, this study set out to assess the cost-effectiveness of sorafenib as a first-line treatment of hepatocellular carcinoma (HCC) compared to best supportive care (BSC) from the military hospital perspective in Egypt. Methods A decision analytic Markov model simulated disease progression with clinical parameters and utility values derived from published data. Data on direct medical costs were collected from the local health care system or payer. Costs and effects were discounted at 3.5% annually and reported in USD using purchasing power parity adjustments. Deterministic and probabilistic sensitivity analyses were conducted. Results Mortality occurred less frequently in the sorafenib group (sorafenib group: 99.96%, BSC group: 99.99%). The total quality-adjusted life years (QALYs) of the sorafenib cohort were estimated to be 46.24 compared with 42.27 for the BSC cohort, which resulted in an incremental gain of 3.96 QALYs. The total costs for the sorafenib and BSC cohorts were USD 4,229,940 and USD 3,092,886, respectively (incremental cost = $1,137,054), resulting in an incremental cost-effectiveness ratio (ICER) of USD 286,776 per QALY gained for the sorafenib cohort. One-way sensitivity analyses that addressed the uncertainty of the BSC estimates indicated that the progression-free survival for BSC and utility value of progression had the greatest effects on the results. Conclusion This study concluded that sorafenib does offer increased survival and quality of life at an increased cost but at an ICER that exceeds the nationally accepted cost-effectiveness threshold. Our findings support health care decision-making of the efficient allocation of health care system resources to improve the health of the Egyptian population. Whether sorafenib is cost-effective in specific subgroups with additional risk factors needs to be addressed in future studies.

PMID: 30479174 [PubMed - as supplied by publisher]

from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2ShVlsO